Astrazeneca annual free cash flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Astrazeneca Free Cash Flow (FCF) History (AZN)
Astrazeneca reported $11.77B in free cash flow for fiscal 2025, an increase of 18.40% from the previous fiscal year, with a free cash flow margin of 20.03%.
View full Astrazeneca company overviewAstrazeneca free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | $11.77B | $1.83B | +18.40% | +20.03% |
| 2024 | 2024-12-31 | $9.94B | $953.0M | +10.61% | +18.38% |
| 2023 | 2023-12-31 | $8.98B | $267.0M | +3.06% | +19.61% |
| 2022 | 2022-12-31 | $8.72B | $3.85B | +78.92% | +19.65% |
| 2021 | 2021-12-31 | $4.87B | $1.03B | +26.94% | +13.02% |
| 2020 | 2020-12-31 | $3.84B | $1.85B | +92.86% | +14.42% |
| 2019 | 2019-12-31 | $1.99B | $415.0M | +26.35% | +8.16% |
| 2018 | 2018-12-31 | $1.57B | −$677.0M | −30.06% | +7.13% |
| 2017 | 2017-12-31 | $2.25B | −$447.0M | −16.56% | +10.02% |
| 2016 | 2016-12-31 | $2.70B | $703.0M | +35.22% | +11.73% |
| 2015 | 2015-12-31 | $2.00B | — | — | +8.08% |
Astrazeneca quarterly free cash flow
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$240.0M | −$1.70B | — | −1.56% |
| Q1 2026 | 2026-03-31 | $1.82B | — | — | +11.91% |
| Q4 2025 | 2025-12-31 | $1.05B | — | — | +6.81% |
| Q3 2025 | 2025-09-30 | $3.41B | — | — | +22.43% |
| Q2 2025 | 2025-06-30 | $1.46B | — | — | — |
Astrazeneca free cash flow growth trends
Over the last five reported fiscal years, free cash flow grew from $3.84B to $11.77B, a compound annual growth rate of 25.11%. Astrazeneca's latest reported quarter, Q2 2026, generated −$240.0M in free cash flow, a decrease of $1.70B year over year.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Astrazeneca source filings ↗Community posts
AstraZeneca receives priority review for perioperative bladder-cancer regimen
The FDA granted priority review to a regimen combining AstraZeneca ($AZN)’s Imfinzi with enfortumab vedotin around surgery for muscle-invasive bladder cancer in patients ineligible for, or declining, cisplatin chemotherapy. Imfinzi is given ...
AstraZeneca’s Klygefa receives a positive EU recommendation
European medicines advisers recommended AstraZeneca ($AZN)’s Klygefa, or gefurulimab, as an add-on to standard treatment for adults with generalized myasthenia gravis who are positive for anti-acetylcholine receptor antibodies. The Alexion ...
Enhertu receives European recommendation for an earlier breast-cancer setting
European advisers recommended Enhertu for postoperative treatment of adults with HER2-positive breast cancer who still have invasive disease after preoperative taxane-based chemotherapy and HER2-directed treatment. The drug is jointly devel ...
AstraZeneca receives US accelerated approval for Etcamah in a defined breast-cancer setting
AstraZeneca announced US accelerated approval of Etcamah on 7 September 2026. Approved setting Camizestrant, combined with a CDK4/6 inhibitor, is approved for adults with HR-positive, HER2-negative locally advanced or metastatic breast canc ...
